DIFFUSE LARGE B-CELL LYMPHOMA (DLBL / DLBCL) (30-50% of all NHLsref1, ref2) : large cleaved and noncleaved cells in a diffuse pattern of infiltration; it is similar to the diffuse mixed variety and has an intermediate grade of malignancy (aggressive, high grade malignancy)

Table of contents :

  • Epidemiology
  • Pathogenesis
  • Symptoms & signs
  • Laboratory examinations
  • Therapy 
  • Prognosis
  • Web resources

  • Epidemiology : average onset at age 70
    Pathogenesis :

    Laboratory examinations :

    Therapyref : anthracycline-based chemotherapy Prognosis : aggressive; durable remissions are achieved in only 40% to 50% of patientsref. BCL2, p53or Ki67 represent unfavorable prognostic factors. 36 genes are predictive for drug response : 6 genes related to blood production, inflammation, metastasis, protein production, and immune system regulation correlate most closely with patients' survivalref. Patients with DLBCL have an extremely variable clinical outcome using standard adriamycin-containing chemotherapy, ranging from cure to treatment failure, relapse, and death. While the median survival for all patients treated with such regimens is approximately 4 years, survival can range from a few weeks to > 10 years when the disease is cured. This variability in clinical outcome suggests marked intertumoral heterogeneity. This heterogeneity is reflected, to a limited extent, by the morphologic classification of DLBCL. Differential diagnosis : metastatic anaplastic carcinomas
    Web resources : DLBCL at LymphomaInfo

    Copyright © 2001-2014 Daniele Focosi. All rights reserved Terms of use  | Legal notices
    About this site  |  Site map  |  AcknowledgementsCurrent link partners
     Abbreviations and acronyms  |  Medical terminology  |  Add a link  |  Translate   |  Softwares Cite this page!

    Rate Us:

    This website subscribes to the HONcode principles of the HON Foundation. Click to verify.eXTReMe Tracker


    Search Medical Dictionary